With increasing representation of women in medicine, recent efforts have attempted to determine whether women are adequately represented among leaders of academic medicine and published studies.1-3 We studied the representation of female lead authors for oncologic phase 3 randomized clinical trials (RCTs) because trial leadership affects promotion and tenure, prominence in the field, and access to subsequent funding opportunities. We quantified the proportion of RCTs led by women over time and determined factors associated with female corresponding authorship (FCA) among oncologic RCTs.
Ludmir EB, Mainwaring W, Miller AB, et al. Women’s Representation Among Lead Investigators of Clinical Trials in Oncology. JAMA Oncol. Published online August 08, 2019. doi:10.1001/jamaoncol.2019.2196
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: